The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment.
about
miRNAs Participate in MS Pathological Processes and Its Therapeutic ResponseExpression, regulation and function of microRNAs in multiple sclerosisGlatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.Islamic fasting and multiple sclerosis.Modern analytics for synthetically derived complex drug substances: NMR, AFFF-MALS, and MS tests for glatiramer acetate.The heritage of glatiramer acetate and its use in multiple sclerosis
P2860
The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment.
@en
type
label
The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment.
@en
prefLabel
The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment.
@en
P2860
P1476
The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment.
@en
P2093
Francesco Patti
Silvia Messina
P2860
P304
P356
10.1517/17425255.2013.811489
P407
P577
2013-06-25T00:00:00Z